{"links":{"html":"https://www.erudio.com/reports/dumas-nct05684276","json":"https://www.erudio.com/reports/dumas-nct05684276.json","markdown":"https://www.erudio.com/reports/dumas-nct05684276.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"dumas-05684276"}},"request":"https://www.erudio.com/contact?report=dumas-05684276"},"offer":{"cited_commentary_sources":8,"verified_hcp_statements":17,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":3,"optional":true,"price_per_verified_person_usd":15,"price_usd":45,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"dumas-nct05684276"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dumas-05684276","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dumas-nct05684276","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T02:01:52.249252Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":2},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Estimate progression-free survival (PFS)"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":1,"title":"Secondary endpoint: Overall survival"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)"},{"claim_count":1,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":1,"title":"Secondary endpoint: Complete resection (R0) rate"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":5,"title":"Pathological response and surgical uptake"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":4,"title":"Clinical implications and readiness to change care"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Surgical expertise and routine-care translation"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":3,"title":"Evidence generation and comparative-study feasibility"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Pride in Spanish research"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"interpretation":4,"opinion":6,"primary_context":1,"question":1,"restatement":5},"claims_by_kind":{"protocol_statement":1,"source_observation":16},"clinician_statements":3,"evidence_units":13,"findings":5,"organisational_accounts":2,"people_cited":5,"people_identity_verified":3,"people_total":5,"screened_sources":49,"verified_claims":17},"findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":5},"has_counterview":false,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Clinical implications are asserted alongside a request for more mature survival"},{"id":"F2","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":1},"has_counterview":false,"limitations":3,"links":{"context":1,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Response denominators and differing survival summaries limit a single numerical reading"},{"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":4},"has_counterview":false,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"The treatment-change question is qualified by surgical expertise"},{"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":2},"has_counterview":false,"limitations":2,"links":{"context":1,"support":4},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Prospective evidence is valued against a difficult comparative-evidence backdrop"},{"id":"F5","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":1,"links":{"context":1,"support":1},"ma_question":false,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A supportive reply celebrates Spanish research rather than a treatment decision"}],"medical_affairs_question":"What additional survival maturity, comparative evidence and surgical expertise would justify a defined change in Pancoast care?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinical relevance is asserted, but the proposed practice consequence remains unspecified"},{"id":"section-2","level":2,"title":"Numerical enthusiasm requires denominator and endpoint separation"},{"id":"section-3","level":2,"title":"Surgical expertise qualifies the question of changing Pancoast care"},{"id":"section-4","level":2,"title":"The value of prospective evidence is paired with concern about randomized feasibility"},{"id":"section-5","level":2,"title":"Support for Spanish research is a distinct, nonclinical reaction"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Estimate progression-free survival (PFS)"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T2","label":"Secondary endpoint: Overall survival"},{"findings":[],"id":"T3","label":"Secondary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T4","label":"Secondary endpoint: Complete resection (R0) rate"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T6","label":"The comparison"},{"findings":[],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T02:01:52.249252Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T02:16:01Z","record_hash":"1e42f0416898a498c0f4690944bfccaeff3419935a9e4fbca5812f6d32425a28","release_hash":"08ac526ccaf7df0e461e4843a3563d0846bcd946d6ceb5acfca74f2d9e7a8422","report_id":"erudio-nct05684276","run_id":"a821d073-039b-4004-ad5f-996fc10a3375","schema_version":"5.0","slug":"dumas-05684276","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on DUMAS in the sources reviewed for this edition leads to one open question: What additional survival maturity, comparative evidence and surgical expertise would justify a defined change in Pancoast care? Its leading findings: (1) clinical implications are asserted alongside a request for more mature survival. (2) response denominators and differing survival summaries limit a single numerical reading. (3) the treatment-change question is qualified by surgical expertise. 2 more findings follow. 49 sources screened, 9 cited; not all HCPs or all public discussion.","meta_description":"49 sources screened · 17 verified statements (3 from clinicians verified by NPI or staff page) from 9 sources · 5 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-30T02:16:01Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":49},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Coverage is limited to the sources reviewed for this edition. Discussion that does not explicitly name the trial may be missing, and some available passages were not fully evaluated.","No original DUMAS results publication was identified for this edition, and the registry did not list a separate protocol document. Numerical outcomes are discussed through social-media summaries.","The sources do not explain the different reported PFS figures, and some response and survival percentages lack a denominator, endpoint subtype or timepoint.","The reviewed statements provide no adverse-event or tolerability assessment; favorable response and survival reactions do not establish a favorable safety profile.","The separate Pancoast case cohort and SWOG comparison provide treatment-choice context, not DUMAS outcomes.","Some authors' clinical roles are not established. Organizational coverage, presentation relays and reposts cannot be treated as independent HCP opinions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":8,"methods":1},"count":9,"evidence_window":{"end":"2026-09-15","start":"2025-02-03"},"retrieval_snapshot":"2026-10-29T20:01:38.000991Z","timeline":[{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2026-W36"},{"count":4,"week":"2026-W38"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05684276:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05684276:context","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"openfda:e4be6cbf-72b9-4f7f-9b1b-459b2d35961a:20260909","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3visyg3ohmxynpqwtr4tx3ov-3lxhsxtztu224","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-f23wyrgrfywfyqjwbe6extpq-3lcycyydnsk2t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-i7g62qhqwyobrqzg63yyz7vf-3mfwsblt3rc24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-i7g62qhqwyobrqzg63yyz7vf-3mvilvta3mk2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-m2p3dwd2n7bao4lzvsuslzkr-3lj5z24eevc2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o7wsojxuoebg6qxsoqszuulg-3lnbtafxisc2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pxp52aqigla7dd54fwsc5noj-3lvvudq3jbc2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qvzn322kmcvd7xtnips5xaun-3mviangq5cc2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tize5g7mq5j2l57cuxsmtwbl-3lhe5nvwblk2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-wcdjqlsqi246ngdted6ajj7b-3lhe5peawvk2f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6c8470","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:729339","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b3bb48","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:dfd7bd","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e7de50","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ea4830","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651279118489600019:c533104a-f34e-4a3c-9728-d7eab6330ac1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651340063035252738:55e2dea3-67f7-49fb-a992-54873c05fb00","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1675098421911490560:4b117532-0ba4-4830-8d4a-e5a45e017f46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708403124770091266:20d0679f-61fd-44d1-90d8-2d60cd19dbcc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1732154620045136261:0493fb7d-b04e-41dd-9f89-bfbc59a758dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1791125383460298940:2d6d580f-1143-4bdd-ba1a-063583a50274","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1791535757758235093:cc83436c-54b6-47d3-976a-00018a594bd9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834872253126693119:f5960b8b-09e6-4340-bb67-25afe50801aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834888318946808298:6fdb2f11-3038-4d6a-ab42-801228084fab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1886505552290673009:56a4911e-d21b-4e78-827f-31e62e4ddd40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1909939094320218354:c3848d0a-8038-447e-ab3f-c1d1e4bfeeac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919421838154928203:a225b282-7cd6-4ee8-8538-758f095a8122","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1959933866052849797:0eb55f97-a0d5-4dc4-826e-c48d05c9bdbc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1963935999639060949:eef77d6e-d8c6-499b-b73c-60d63f2bf800","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981393366634954772:191eea5f-bf5c-495a-b766-7620a6c009e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981395237265150059:1771b5f1-8840-421a-9fe2-d40d4414c8cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981442052685508621:7c1d7b9c-d5a3-40bc-8d37-6b93f5cd3b9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2023527178735153300:9430aa9e-5a97-4ac5-822c-6274453c930f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2028727432438534403:a13eaced-fbd8-4192-a144-e069fc29e919","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055314525990109474:d1af4dfa-584e-4d3c-b07b-d4a7e55224a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092974907374322171:171b2ea1-0b4f-466b-82e8-42171ea87e72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094364726318776678:7bfc90b0-05cf-4d53-a183-a12a23ad7742","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095542659628630306:e82f1b89-73d6-49d5-9eec-507a350172fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098006142118928647:aba2fd21-ddc2-4afd-9e5d-84212afd5783","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098736931328622608:362ae04e-7b2d-4caa-8658-51f16507f768","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099401828169621943:f64f96ef-682c-49b9-9d1d-64af3a88c8f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099405636970897838:5332f944-c8db-4f82-85a4-129565df3545","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099410275166191760:b98991f9-dfcb-4c3e-9bd8-419efbdf8b54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099468688243986741:40ef9c06-d379-4090-b721-b2332e0028b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099844850233581875:14a3e6eb-7a68-4ee7-9b74-a1099f17724c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111161006047347078:040c90d3-f606-49c0-be9d-8bc58cfbac4a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aX43vd1_R5M","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:u2tmX7AMgI8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":10,"linkedin_post":0,"other":0,"podcast":6,"publication":0,"registry":0,"regulatory":0,"x_thread":31,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":49},"count":49,"evidence_window":{"end":"2026-10-16","start":"2023-03-20"},"retrieval_snapshot":"2026-10-29T20:55:06.529794Z","timeline":[{"count":1,"week":"2023-W12"},{"count":2,"week":"2023-W17"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W30"},{"count":1,"week":"2023-W31"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W49"},{"count":2,"week":"2024-W20"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2024-W50"},{"count":3,"week":"2025-W06"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W19"},{"count":2,"week":"2025-W30"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W32"},{"count":2,"week":"2025-W35"},{"count":1,"week":"2025-W36"},{"count":3,"week":"2025-W43"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":7,"week":"2026-W38"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"}],"indications":[{"reason":"Unmapped registry condition: NSCLC","status":"unmapped"},{"reason":"Unmapped registry condition: Pancoast Tumor","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"DUMAS","aliases":["DUMAS","DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors","Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study"],"brief_title":"DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["NSCLC","Pancoast Tumor"],"display_condition":"NSCLC with Pancoast tumor","display_interventions":[["nivolumab","carboplatin","paclitaxel"]],"enrollment":{"count":22,"type":"ESTIMATED"},"interventions":[{"name":"Carboplatin","synonyms":["Paraplatin"],"type":"DRUG"},{"name":"Paclitaxel","synonyms":["Taxol"],"type":"DRUG"},{"name":"Nivolumab","synonyms":["Opdivo"],"type":"DRUG"}],"nct_id":"NCT05684276","official_title":"Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-03-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"The PFS is defined as the time from diagnosis to relapse, progression or death, whichever occurred first","measure":"Estimate progression-free survival (PFS)","timeFrame":"From the date randomization until the date of last follow up, assessed up to 24 months"}],"registered_date":{"date":"2023-01-13","type":"ACTUAL"},"registry_last_updated":"2026-05-05","registry_url":"https://clinicaltrials.gov/study/NCT05684276","short_name":"DUMAS","short_name_basis":"registry_acronym","sponsor":"Fundación GECP","start_date":{"date":"2023-05-12","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"GECP 22/02_DUMAS","type":"sponsor_study_id"},{"id":"2022-003717-11","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}